This content is from: Premium
This is the IPO Market’s Healthy Corner
At least four hedge fund firms are gearing up for biopharma IPOs planned for the next two weeks.
Some high-profile IPOs are under attack — but hedge funds are finding opportunity in more obscure parts of the market.At least one unicorn — We, the parent of WeWork — scrapped its planned initial public offering amid reports that its lofty valuation is being sharply marked down, while other high-profile
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.